« Back to Research Deepdives

DiRECT Study: Liver Fat and Remission of Type-2 Diabetes

This content is restricted to members.

To view our premium content, sign up for a membership:


Register New Account

Choose your membership level

Choose Your Payment Method

‹ Back to Research Deepdives


1. Top 10 causes of death [Internet]. World Health Organization. 2020 [cited 13 August 2020]. Available from: https://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/
2. Nowakowska M, Zghebi S, Ashcroft D, Buchan I, Chew-Graham C, Holt T et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Medicine. 2019;17(1).
3. Cantley J, Ashcroft F. Q&A: insulin secretion and type 2 diabetes: why do β-cells fail?. BMC Biology. 2019;17(1).
4. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837-853.
5. Lean M, Leslie W, Barnes A, Brosnahan N, Thom G, McCombie L et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology. 2019;7(5):344-355.
6. Kotronen A, Yki-Järvinen H. Fatty Liver. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(1):27-38.
7. Lim E, Hollingsworth K, Aribisala B, Chen M, Mathers J, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54(10):2506-2514.
8. Xin Y, Davies A, Briggs A, McCombie L, Messow C, Grieve E et al. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. Diabetologia. 2020.